Heart Failure
66 programs · 63 companies
Programs
66
Companies
63
Trials
54
MOAs
42
EGFRiEZH2iKRASG12CiFcRniBETiIL-13iIL-23iCD3xCD20WRNiSOS1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Phase 2/3 | GIP-R | ||
| Adagrazumab | Phase 2/3 | Cl18.2 | ||
| Gozelemzoparlimab | Phase 2 | FXIa | ||
| ABB-2476 | Phase 1/2 | USP1 | ||
| Sovarapivir | Phase 2/3 | IL-13 | ||
| Gozesotorasib | NDA/BLA | HER2 | ||
| Motarapivir | Preclinical | AuroraA | ||
| GSK-2051 | Phase 1 | PSMA | ||
| Pexamavacamten | NDA/BLA | TIGIT | ||
| AMG-2752 | Preclinical | MDM2 | ||
| GIL-2011 | Preclinical | VEGF | ||
| REG-6699 | Phase 2/3 | TIM-3 | ||
| VRT-1891 | Phase 1 | KRASG12C | ||
| INC-1582 | Phase 1/2 | APOC3 | ||
| 180-6098 | Phase 1 | ALK | ||
| Sematenlimab | Phase 3 | PI3Kα | ||
| 207-2754 | Phase 1/2 | KRASG12D | ||
| Elralucimab | Phase 2 | CDK4/6 | ||
| PRA-419 | Approved | Cl18.2 | ||
| AKR-4818 | Approved | CD20 | ||
| Lisorapivir | Approved | AuroraA | ||
| Rilutinib | Phase 3 | PD-L1 | ||
| Lisozanubrutinib | NDA/BLA | CD20 | ||
| GRF-8977 | Phase 1 | FcRn | ||
| NCI-IIT-415 | Preclinical | GIP-R | ||
| SEO-IIT-219 | Approved | SMN2 | ||
| MAS-IIT-787 | Phase 1 | GPRC5D | ||
| Olpazasiran | Preclinical | DLL3 | ||
| Datofutibatinib | Approved | GLP-1R | ||
| CLL-5354 | Preclinical | FcRn | ||
| NBY-4130 | Phase 3 | IL-17A | ||
| MEI-1770 | Phase 2/3 | PCSK9 | ||
| BSG-8809 | Approved | Nectin-4 | ||
| DMA-2916 | Phase 1/2 | CD38 | ||
| Cevifutibatinib | Phase 3 | SOS1 | ||
| AGO-8938 | Phase 2 | BET | ||
| KMD-8521 | Preclinical | BCL-2 | ||
| PRT-4395 | Phase 2 | GPRC5D | ||
| 699-6202 | Phase 1/2 | TROP-2 | ||
| Niracagene | Preclinical | BCL-2 | ||
| Lisocilimab | Phase 2/3 | FXIa | ||
| INT-3699 | Preclinical | GPRC5D | ||
| Terazanubrutinib | Preclinical | SMN2 | ||
| MAP-6526 | Approved | PD-1 | ||
| 4D-8297 | Phase 1/2 | GPRC5D | ||
| MRE-2348 | Preclinical | FXIa | ||
| CAL-5800 | Phase 1/2 | GLP-1R | ||
| Tixacapivasertib | Approved | Tau | ||
| TRI-2500 | Phase 1/2 | AHR | ||
| BER-6819 | Phase 2/3 | PRMT5 | ||
| Lisolemzoparlimab | Preclinical | CD3 | ||
| NEO-1781 | NDA/BLA | DLL3 | ||
| TXM-5550 | NDA/BLA | KRASG12C | ||
| Gelisacituzumab | Phase 1 | AuroraA | ||
| GRF-8988 | Phase 2/3 | CD20 | ||
| JUB-6434 | Phase 1 | MDM2 | ||
| BIO-IIT-463 | Approved | Nectin-4 | ||
| SIA-2247 | Preclinical | FLT3 | ||
| NAT-IIT-627 | Phase 1 | CD47 | ||
| HOS-IIT-591 | Phase 3 | LAG-3 | ||
| Tiratuximab | Phase 2 | HER2 | ||
| Bemasertib | Phase 3 | Nectin-4 | ||
| Ivonaritide | Phase 2 | CDK4/6 | ||
| ELA-1012 | NDA/BLA | KRASG12D | ||
| AMY-7629 | Phase 2/3 | KIF18A | ||
| QTR-9473 | Approved | GLP-1R |
Trials (54)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08229380 | JNJ-5094 | Phase 2/3 | Recruiting |
| NCT07375262 | Adagrazumab | Phase 2/3 | Active |
| NCT08534549 | Gozelemzoparlimab | Phase 2 | Active |
| NCT05032053 | Sovarapivir | Phase 2/3 | Completed |
| NCT07268818 | Motarapivir | Preclinical | Terminated |
| NCT04024918 | Motarapivir | Preclinical | Completed |
| NCT08113525 | Pexamavacamten | NDA/BLA | Terminated |
| NCT08209580 | Pexamavacamten | NDA/BLA | Completed |
| NCT08780111 | GIL-2011 | Preclinical | Not yet recr... |
| NCT03005777 | GIL-2011 | Preclinical | Not yet recr... |
| NCT04606202 | VRT-1891 | Phase 1 | Recruiting |
| NCT08900793 | VRT-1891 | Phase 1 | Completed |
| NCT07126250 | INC-1582 | Phase 1/2 | Active |
| NCT07666509 | Sematenlimab | Phase 3 | Active |
| NCT07585831 | Sematenlimab | Phase 3 | Terminated |
| NCT05946995 | Elralucimab | Phase 2 | Completed |
| NCT04290607 | Lisorapivir | Approved | Recruiting |
| NCT03704654 | Rilutinib | Phase 3 | Not yet recr... |
| NCT04619190 | Lisozanubrutinib | NDA/BLA | Not yet recr... |
| NCT04700288 | NCI-IIT-415 | Preclinical | Recruiting |